Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 156-163

  Tilanus Linthorst, Madeleine M A ^a   Lingsma, Hester F ^a   Evans, D Gareth ^b   Thompson, Deborah ^c   Kaas, Reinoutje ^d   Manders, Peggy ^e   Van Asperen, Christi J ^f   Adank, Muriel ^g   Hooning, Maartje J ^a   Kwan Lim, Gek E ^h   Eeles, Rosalind ^h   Oosterwijk, Jan C ⁱ   Leach, Martin O ^h   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

age at onset; BRCA1; BRCA2; breast cancer; prevention; screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ONCOGENE BRCA2; ONSET AGE; PRIORITY JOURNAL; SECOND DEGREE RELATIVE; STATISTICAL MODEL; WOMEN'S HEALTH;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; NETHERLANDS; RISK ASSESSMENT; RISK FACTORS;

EID: 84876672300     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28014     Document Type: Article

References (32)

1. Claus EB, Risch N, Thompson WD,. Autosomal dominant inheritance of early onset breast cancer. Cancer 1994; 73: 643-51.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analyses of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
4. Milne RL, Osorio A, Cajal TR, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008; 14: 2861-9.
5. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
6. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 2000; 83: 1301-8.
7. Jacobi CE, de Bock GH, Siegeink B, et al. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose ? Breast Cancer Res Treat 2009; 115: 381-90.
8. Brandt A, Bermejo JL, Sundquist J, et al. Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start. Breast Cancer Res Treat 2010; 121: 133-41.
9. Peto J, Mack ThM,. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26: 411-4.
10. Bordeleau PS, Poll A, Llacuachaqui M, et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet 2010: 77: 273-79.
11. Saslow D, Boetes C, Burke W, et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clinic 2007; 57: 75-89.
12. NAtionaal Borstkanker Overleg Nederland: Richtlijn mammacarcinoom 2008. Available at http://www.cbo.nl.
13. NICE guideline: Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care National Institute for Health and Clinical Excellence. Clinical guidelines CG41. Issued: October 2006 updated from original comprehensive guidance CG14 June 2004. Available at: www.nice.org.uk/guidance/CG41.
14. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound and other technologies for the use of clinically occult breast cancer. J Am Coll Radiol 2010; 7: 18-27.
15. Mann RM, Kuhl CK, Kinkel K, et al. Breast MRI: guidelines from the European Society of breast imaging. Eur Radiol 2008; 18: 1307-18.
16. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089-96.
17. Rijnsburger AJ, Obdeijn A-I, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA-2 associated and familial cases: long-term follow-up of the Dutch MRISC screening study. J Clin Oncol 2010; 28: 5265-73.
18. Peter C, Jack V, David A,. Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? Am Heart J 2003; 145: 27-35.
19. Zhou X, Perkins AJ, Hui SL,. Comparisons of software packages for generalized linear multilevel models. Am Stat 1999; 53: 282-90.
20. O'Connor TG, Dunn J, Jenkins JM, et al. Predictors of between-family and within-family variation in parent-child relationships. J Child Psychol Psychiatry 2006; 47: 498-510.
21. Lingsma HF, Steyerberg EW, Eijkemans MJ, et al. Netherlands Stroke Survey Investigators. Comparing and ranking hospitals based on outcome: results from The Netherlands Stroke Survey. QJM 2010; 103: 99-108.
22. Leach MO, Boggis CR, Dixon AK, et al. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
23. Evans DGR, Lennard F, Pointon LJ, et al. UK Study of MRI Screening for Breast Cancer in Women at High Risk (MARIBS). Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous testing on breast cancer incidence in the MARIBS study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2123-31.
24. Wang X, Pankratz VS, Fredericksen Z, et al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2010; 19: 2886-97.
25. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumour subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 250-63.
26. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29: 1664-9.
27. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007; 13: 7357-62.
28. Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 2013; 118: 321-5.
29. De Bock GH, Jacobi CE, Seynaeve C, et al. A family history of breast cancer will not predict female early onset breast cancer in a population-based setting. Biomed Chromatogr Cancer 2008; 8: 203.
30. John EM, Phipps AI, Knight JA, et al. Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry. Int J Cancer 2007; 121: 386-94.
31. De Gelder R, Draisma G, Heijnsdijk EAM, et al. Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br J Cancer 2011; 104: 1214-20.
32. Schousboe JT, Kerlikowske K, Loh A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med 2011; 155: 10-20.